Sign In
Buy AXGN
$40.63
+1.17 (+2.97%)
At Close: Jun 03, 2026
ArrowMark Colorado Holdings LLC Buys 332,498 Shares of AxoGen, Inc. $AXGN
03:52am, Sunday, 15'th Mar 2026
ArrowMark Colorado Holdings LLC grew its stake in AxoGen, Inc. (NASDAQ: AXGN) by 20.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Com
AxoGen Says BLA Approval Secures Avance Use, Boosts Coverage Talks and Reimbursement Momentum
01:14am, Saturday, 14'th Mar 2026
AxoGen (NASDAQ: AXGN) executives said a newly secured Biologics License Application (BLA) approval has preserved the company's ability to serve patients across a broad range of peripheral nerve repair
AxoGen Touts FDA BLA Win, Targets 18% Growth and Wider Nerve Repair Adoption at Raymond James Conference
04:48am, Saturday, 07'th Mar 2026
AxoGen (NASDAQ: AXGN) used its presentation at the 47th annual Raymond James Institutional Investors Conference to outline its mission to make restoration of peripheral nerve function an expected stan
Axogen, Inc. (AXGN) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
11:15am, Friday, 06'th Mar 2026
Axogen, Inc. (AXGN) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
Axogen Q4: EPS Miss Amid Biologics Transition
05:23am, Wednesday, 25'th Feb 2026
Axogen, Inc. (AXGN) reported strong 21% revenue growth but missed EPS expectations, prompting an 8% share decline and highlighting near-term margin pressures. AXGN is transitioning to a regulated biol
Axogen, Inc. (AXGN) Q4 2025 Earnings Call Transcript
11:37am, Tuesday, 24'th Feb 2026
Axogen, Inc. (AXGN) Q4 2025 Earnings Call Transcript
AxoGen (AXGN) Q4 Earnings Miss Estimates
10:41am, Tuesday, 24'th Feb 2026
AxoGen (AXGN) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.08 per share a year ago.
HighMark Wealth Management Buys 158,855 Shares of Axogen Stock
08:59am, Tuesday, 24'th Feb 2026
This healthcare firm delivers surgical solutions for peripheral nerve repair, targeting specialized surgeons across U.S. and global markets.
First Eagle Small Cap Opportunity Fund Q4 2025 Portfolio Review
02:27pm, Thursday, 19'th Feb 2026
First Eagle Small Cap Opportunity Fund A Shares (without sales charge*) posted a return of 1.71% in fourth quarter 2025. Small Cap Opportunity Fund A Shares (without sales charge*) posted a return of
Principal Financial Group Inc. Purchases 21,002 Shares of AxoGen, Inc. $AXGN
03:32am, Thursday, 19'th Feb 2026
Principal Financial Group Inc. raised its holdings in AxoGen, Inc. (NASDAQ: AXGN) by 69.7% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
07:00am, Tuesday, 17'th Feb 2026
ALACHUA, Fla. and TAMPA, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of periphera
Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
07:00am, Tuesday, 10'th Feb 2026
ALACHUA, Fla. and TAMPA, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of periphera
Wasatch Micro Cap Fund Q4 2025 Performance Review
08:35am, Wednesday, 04'th Feb 2026
Leading individual contributors to the Fund's relative performance included Axogen, Inc., a holding within the health-care equipment industry. A provider of prepared food items such as meatballs and p
Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock
11:18pm, Wednesday, 21'st Jan 2026
ALACHUA, Fla. and TAMPA, Fla.
Axogen Announces Proposed Public Offering of Common Stock
04:09pm, Wednesday, 21'st Jan 2026
ALACHUA, Fla. and TAMPA, Fla.
